After reviewing MAPS’ Type A Meeting Request and Briefing submitted on April 28, the FDA granted MAPS’ meeting request. MAPS and the FDA will have a face-to-face formal meeting to discuss the …
Explore “Deep Space” With Dr. Bronner’s Attendees are encouraged to explore events including live music, breathwork sessions, yoga, meditation, art, film screenings, dance parties, mindfulness ceremonies, …
On April 28, 2023, MAPS requested the FDA for a Type A meeting to discuss the clinical hold issues for Study MJP2 in order to overcome the clinical hold deficiencies. This meeting request is in response …
Today, Psychedelic Science 2023, the breakthrough psychedelic conference hosted by Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced its sessions …
“You and I are the force for transformation in the world. We are the consciousness that will define the nature of the reality we are moving into.” Ram Dass Today is MAPS’ 37th anniversary! Almost …
FOR IMMEDIATE RELEASE: April 5, 2023 MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), announced preliminary findings …
Rock Star and Activist to speak about addiction, family, and the healing potential of plant medicine FOR IMMEDIATE RELEASE: March 17, 2023 SOURCE: Psychedelic Science Today, Psychedelic Science 2023, the …
On March 14, 2023, MAPS released a progress report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). Read the Q4 2022 progress report here.
Super Bowl Champion Quarterback Aaron Rodgers, Author & Journalist Michael Pollan, U.S. Olympian Sasha Cohen, Co-Founder of Whole Foods John Mackey, Lieutenant Diane M. Goldstein (Ret.), and Famed …
Distinctions in Australian MDMA and Psilocybin Policy The Therapeutic Goods Administration (TGA) in Australia recently announced a new policy allowing for the limited use of psychedelic-assisted therapies …
FOR IMMEDIATE RELEASE: February 3, 2023 The Therapeutic Goods Administration (TGA) in Australia announced today that they will permit limited use of certain psychedelic-assisted therapies for the treatment …
On January 19, 2023, the FDA advised MAPS that cannabis used in clinical trials is defined as a drug product, rather than a botanical raw material, for the purposes of microbiological testing acceptance …
